WAVEMAN · COMPANY

BVS · Bioventus Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

BVS

Name: Bioventus Inc. (BVS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Bioventus Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001665988

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$105.5K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

103

13F, latest reported quarter

REVENUE GROWTH

-0.9%

XBRL, annual

NET MARGIN

4.0%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$105.5K over 180 days

more than 60% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

103 funds added or opened last quarter

more than 58% of Medical Devices

REVENUE

-0.9% year over year

below 75% of Medical Devices

MARGIN

4.0% net margin

more than 67% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

3.9 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

103 funds added or opened positions in the latest 13F quarter, of 158 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +94.9%

+94.9%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $105.5K sold by insiders over 180 days, 103 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Bioventus Inc. insiders sold a net $105.5K of stock across 70 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

McMurry-Heath Michelle

Director

SELL

2026-03-11

12,000.0

$105.5K

NOHRA GUY P

Director

SELL

2025-12-04

10,000.0

$75.7K

McMurry-Heath Michelle

Director

SELL

2025-11-07

17,701.0

$131.3K

Singleton Mark Leonard

SVP & CFO

SELL

2025-04-11

3,875.0

$29.3K

D'Adamio Anthony

SVP & General Counsel

SELL

2025-04-11

2,958.0

$22.4K

70 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 65 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Essex Woodlands Management, Inc.

13,021,324.0 sh

$122.9M

Nantahala Capital Management, LLC

12,000,558.0 sh

$113.3M

Juniper Investment Company, LLC

6,939,357.0 sh

$65.5M

BlackRock, Inc.

3,435,914.0 sh

$32.4M

ROYCE & ASSOCIATES LP

1,833,212.0 sh

$17.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Knights of Columbus Small Cap Equity Fund

$2.6M POSITION · AS OF 2026-04-30

1.3%

1290 Essex Small Cap Growth Fund

$1.4M POSITION · AS OF 2026-04-30

1.2%

Royce Small-Cap Opportunity Fund

$7.2M POSITION · AS OF 2026-03-31

0.6%

WesMark Small Company Fund

$894.7K POSITION · AS OF 2026-03-31

0.6%

NORTH SQUARE KENNEDY MICROCAP FUND

$169.2K POSITION · AS OF 2026-02-28

0.6%

Invesco NASDAQ Future Gen 200 ETF

$76.4K POSITION · AS OF 2026-02-28

0.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 3 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$568.1M	$573.3M	$512.3M	$512.1M
GROSS PROFIT	$388.2M	$388.2M	$328.2M	$331.1M
OPERATING INCOME	$54.0M	$-15.2M	$-81.7M	$-167.2M
NET INCOME	$22.7M	$-36.1M	$-156.2M	$-158.7M
EPS (DILUTED)	0.33	-0.56	-2.49	-2.59
OPERATING CASH FLOW	$74.7M	$38.8M	$15.3M	$-13.5M
CASH	$51.2M	$41.6M	$37.0M	$30.2M
LONG-TERM DEBT	$279.0M	$308.3M	$367.0M	$385.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE